Eli Lilly's Manufacturing Expansion and What It Means for Tirzepatide Supply
Eli Lilly has announced multiple new and expanded manufacturing sites tied to GLP-1 production. Here's how capacity investments connect to shortage status.
By the GLP Semaglutide editorial team · Last updated July 30, 2026
Eli Lilly has publicly announced investments in new and expanded manufacturing capacity in the U.S. and abroad specifically tied to meeting demand for tirzepatide (Mounjaro, Zepbound) and its broader injectable drug pipeline.
Capacity and shortage status are linked
New manufacturing capacity generally takes years to come fully online due to regulatory inspection and validation requirements, which is part of why shortage resolution for a given dose strength can lag behind an announced investment by a significant margin.
Tracking current status
The FDA's shortage database reflects current, dose-strength-specific availability status and is a more reliable real-time indicator than manufacturing announcements alone.
Primary sources